The court disputes

Several disputes arose regarding the validity of patent EP’066 and the SPC based on this patent. Lundbeck’s position was that Sipralexa® was a “new” medicinal product, as it was the subject of an entirely separate registration procedure for which it benefited from full data exclusivity.